Pfizer PFE Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.7B— | —— | $3.55B+21.2% | $2.93B-1.5% | $2.97B+611% | ||
| $1.61B-4.4% | $1.69B+1.5% | $1.66B+2.3% | $1.63B+0.4% | $1.62B-9.7% | ||
| $272M+20.9% | $225M+11.9% | $201M-1.0% | $203M+19.4% | $170M-4.0% | ||
| -$12M+97.2% | -$433M+43.4% | -$765M-181% | -$272M+59.0% | -$663M-67.4% | ||
| —— | $65.75M0.0% | $65.75M0.0% | $65.75M0.0% | $65.75M+141% | ||
| —— | -$140.25M0.0% | -$140.25M0.0% | -$140.25M0.0% | -$140.25M-166% | ||
| —— | -$117.25M0.0% | -$117.25M0.0% | -$117.25M0.0% | -$117.25M+54.2% | ||
| —— | -$322.25M0.0% | -$322.25M0.0% | -$322.25M0.0% | -$322.25M+61.9% | ||
| —— | -$916.75M0.0% | -$916.75M0.0% | -$916.75M0.0% | -$916.75M-17.7% | ||
| —— | -$701.25M0.0% | -$701.25M0.0% | -$701.25M0.0% | -$701.25M-109% | ||
| $2.62B-51.1% | $5.35B+16.2% | $4.6B— | $0-100% | $2.34B-65.3% | ||
| $436M-48.4% | $845M+40.4% | $602M-2.6% | $618M+9.6% | $564M-38.5% | ||
| $785M+113% | -$6.15B-153% | -$2.43B-162% | $3.95B+20.7% | $3.27B— | ||
| -$2.86B— | $0+100% | -$2.48B+22.5% | -$3.2B+38.9% | -$5.23B-2.2% | ||
| $19M+280% | $5M+150% | $2M-95.1% | $41M+686% | -$7M+75.9% | ||
| $563M— | —— | —— | $213M-43.2% | $375M+933% | ||
| $293M-70.1% | $981M+257% | $275M-75.7% | $1.13B+220% | $353M-74.7% | ||
| —— | -$117.25M0.0% | -$117.25M0.0% | -$117.25M0.0% | -$117.25M+54.2% | ||
| —— | -$701.25M0.0% | -$701.25M0.0% | -$701.25M0.0% | -$701.25M-109% | ||
| $1.73B— | —— | $36M-99.3% | $4.99B+160% | $1.92B— | ||
| —— | -$322.25M0.0% | -$322.25M0.0% | -$322.25M0.0% | -$322.25M+61.9% | ||
| $93M-20.5% | $117M-59.9% | $292M+189% | $101M+353% | -$40M-102% | ||
| $0— | —— | —— | —— | $6.31B+77.8% | ||
| $173M-53.0% | $368M+338% | $84M-20.0% | $105M-54.1% | $229M— | ||
| $32M-99.3% | $4.41B+1,104% | $366M+138% | $154M-55.2% | $344M-89.1% | ||
| -$22M— | —— | -$14M— | —— | -$300M-1,900% | ||
| $2.57B-36.5% | $4.05B-4.1% | $4.22B+29.5% | $3.26B+15.6% | $2.82B-54.3% | ||
| $4.58B-3.1% | $4.72B+72.6% | $2.74B-58.2% | $6.55B+65.5% | $3.96B+164% | ||
| $88M-85.1% | $591M+64.6% | $359M+470% | $63M-23.2% | $82M+183% | ||
| $0— | —— | —— | —— | $6.31B+77.8% | ||
| $0— | —— | —— | —— | $6.31B+77.8% | ||
| $792M— | —— | $583M— | —— | $3.85B+891% | ||
| $2.45B0.0% | $2.45B0.0% | $2.44B0.0% | $2.45B+0.3% | $2.44B+2.4% | ||
| -$284M-560% | -$43M-13.2% | -$38M-81.0% | -$21M+94.1% | -$356M-2,443% | ||
| -$127M— | —— | —— | -$517M-33.9% | -$386M— | ||
| $0— | —— | —— | $151M-92.6% | $2.05B-40.7% | ||
| $62M+37.8% | $45M-31.8% | $66M— | —— | $74M-49.7% | ||
| $72M-92.9% | $1.02B+471% | $178M-94.7% | $3.34B+2,098% | $152M-64.9% | ||
| $2.18B-51.6% | $4.5B+12.5% | $4B— | —— | $1.77B-69.5% | ||
| $2.18B-51.6% | $4.5B+12.5% | $4B— | —— | $1.77B-69.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Pfizer generate?
- Pfizer (PFE) generated $12.6B in operating cash flow over the trailing twelve months.
- What is Pfizer's free cash flow?
- After $2.5B of capital expenditures, Pfizer's free cash flow was $12.5B over the trailing twelve months, up 26.6% year over year.
- Where does Pfizer's cash flow data come from?
- Every line is extracted from Pfizer's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
